MedPath

A human study to evaluate the efficacy and safety of pollen extract G63® in men with lower urinary tract symptoms

Not Applicable
Completed
Conditions
Diseases of the genitourinary system
Registration Number
KCT0007869
Lead Sponsor
Dankook Univeristy Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
120
Inclusion Criteria

1) A men who agreed to participate in this study and signed a written informed consent
2) A men aged from 40 to under 80
3) A men with lower urinary tract symptoms of mild to moderate lower urinary tract symptoms (IPSS of 1-19)

Exclusion Criteria

1) A men with prostate volume = 40mL
2) A men with serum PSA level =4 ng/mL
3) A men with peak flow rate < 5mL/s
4) A men with post-void residual urine = 150mL
5) A men who takes 5aRI, PDE-5 inhibitor, a-blocker, anticholinergics, beta-3 adrenergic agonist
6) A men who takes health functional foods which can affect prostate health within 1 month of first visit
7) A men with acute prostatitis, urinary tract infection, acute urinary retention, neurogenic bladder, prostate cancer or bladder cancer, etc.

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS),residual urine volume, uroflometry ;NIH-chronic prostatitis symptom index (NIH-CPSI), International index of erectile function-5(IIEF-5), serum PSA
Secondary Outcome Measures
NameTimeMethod
Vital sign;Clinical laboratory test(blood, urine);Adverse event
© Copyright 2025. All Rights Reserved by MedPath